On April 26th, Qianhong Pharmaceutical (002550) recently released its 2023 annual report. During the reporting period, the company achieved business income 1.Legendsultimatemini814268908.89 yuan, down 21.24% from the same period last year; belonging to shareholders of listed companiesLegendsultimateminiThe net profit was 181860747.32 yuan, down 43.77% from the same period last year.
The net cash flow generated by operating activities during the reporting period was 533327999.55 yuan, and the net assets belonging to shareholders of listed companies were 2454931005.01 yuan.
During the reporting period, the board of directors and management agencies strengthened the research and judgment on the impact of drug collection, strengthened the continuous supervision of the strategic positioning of the domestic preparation market and the innovation of marketing strategies in the form of high-level thematic meetings, and the product sales structure was becoming more and more perfect. Continue to make it stronger and bigger. Firmly implement the marketing strategic positioning of enzyme preparations as the core products, steadily expand the sales scale, enhance market share and brand influence. Yikai series of products follow the national guidelines for the treatment of chronic complications of diabetes, implement the marketing strategy of multi-department multi-indication expansion and market academic promotion, and the market share and sales volume continue to rise. In addition to strengthening the hospital brand development, Yikai products actively explore a new mode of OTC strategic cooperation with Bayer Pharmaceutical in Germany, constantly enhance brand awareness and market competitiveness, and further increase sales volume. Heparin sodium injection and sealing solution continue to expand market share and continue to maintain the leading position in the national market share; enoxaparin series products seize the policy opportunity of national collection in time, dominated by rapid market share, and gradually develop into an important economic growth point.
According to the announcement, the remuneration of directors, supervisors and senior managers totaled 12.5585 million yuan during the reporting period. Chairman Wang Yaofang received a total of 369500 yuan in pre-tax compensation from the company, Wang Ke, a director and general manager, received a total of 1.297 million yuan from the company, and Board Secretary Yao Yi received a total of 465400 yuan from the company.
According to the disclosure of the announcement, the profit distribution plan approved by the board of directors is as follows: with a base of 1249800000, it will distribute a cash dividend of 1.20 yuan (including tax) to all shareholders for every 10 shares, and give bonus shares (including tax) to 0 shares (including tax), without using the provident fund to increase share capital.
According to the data of Qianhong Pharmaceutical Network, Qianhong Pharmaceutical's main business scope is as follows: licensing projects: drug production; drug entrusted production; drug wholesale; drug retail; drug import and export (projects that must be approved according to law, business activities can only be carried out with the approval of the relevant departments, and the specific business projects shall be subject to the results of examination and approval). General projects: technology import and export; import and export agents; manufacture of medical packaging materials; purchase of primary agricultural products; technology services, technology development, technology consultation, technology exchange, technology transfer, technology promotion; information consulting services (excluding licensed information consulting services); non-residential real estate rental; housing rental. (except for projects that need to be approved according to law, independently carry out business activities according to law on the strength of business license)